Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Françoise Durrieu

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancers|September 9, 2020
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML PatientsGabriel Etienne, Stéphanie Dulucq, Fréderic Bauduer, et al.
Cytometry. Part B, Clinical Cytometry|October 7, 2011
Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS studyFrançoise Durrieu, Franck Geneviève, Christine Arnoulet, et al.
Cancer Medicine|May 14, 2021
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitorsGabriel Etienne, Carole Faberes, Fréderic Bauduer, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancers|September 9, 2020
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML PatientsGabriel Etienne, Stéphanie Dulucq, Fréderic Bauduer, et al.
Cytometry. Part B, Clinical Cytometry|October 7, 2011
Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS studyFrançoise Durrieu, Franck Geneviève, Christine Arnoulet, et al.
Cancer Medicine|May 14, 2021
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitorsGabriel Etienne, Carole Faberes, Fréderic Bauduer, et al.
Pageof 2